ARID1A and melanoma: More interestingly, our analysis in Melanoma Cohort suggested that receiving PD-1 blockade (nivolumab) resulted in elevated Th17 infiltration (Supplementary Figure S6), which encouraged us to uncover the linkage between ARID1A mutation and response to PD-1 inhibitor.